Skip to main navigation Skip to search Skip to main content

Glutathione triggered degradation of polydopamine to facilitate controlled drug release for synergic combinational cancer treatment

  • Ya Nan Hao
  • , An Qi Zheng
  • , Ting Ting Guo
  • , Yang Shu
  • , Jian Hua Wang
  • , Omar Johnson
  • , Wei Chen
  • Northeastern University China
  • University of Texas at Arlington

Research output: Contribution to journalArticlepeer-review

70 Citations (Scopus)

Abstract

Here we report a novel mechanism for triggering drug release in the polydopamine (PDA)-coated magnetic CuCo2S4 core-shell nanostructure by glutathione (GSH) triggered degradation of PDA for release. In the design, we used PDA coated CuCo2S4 as the nanocarrier with polyethylene glycol and folic acid targeting molecules to ensure the safe delivery of doxorubicin (DOX) to cancer cells. In addition, the controlled release could be enforced by taking advantage of the pH sensitivity of PDA to tumor acidic environments. The targeting and treatment of HeLa cancer cells were very effective and the killing was more efficient at higher levels of GSH. Furthermore, the designed system not only could be used for drug delivery but also could combine photothermal therapy with chemotherapy in a synergetic way. Plus, the system could be used for magnetic resonance imaging (MRI), which is beneficial for imaging-guided treatment.

Original languageEnglish
Pages (from-to)6742-6750
Number of pages9
JournalJournal of Materials Chemistry B
Volume7
Issue number43
DOIs
Publication statusPublished - 2019
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Glutathione triggered degradation of polydopamine to facilitate controlled drug release for synergic combinational cancer treatment'. Together they form a unique fingerprint.

Cite this